THIS BLOG IS ALSO AVAILABLE AS AN AUDIO CAST There’s some good news for a company and a therapeutic approach that CIRM has been supporting for many years. In September 2018, CRISPR Theraputics and ViaCyte entered a partnership to discover, develop and market gene-edited stem cell-derived therapies to treat type 1 diabetes (T1D). Today, they may stand … Continue reading First Patient Dosed in Phase 1 Clinical Trial for T1D